Associazione Qol-One

Address
Via Carro E Quattrone 8

Sponsor Overview

assignment
2
sponsored trials
science
2
molecules
location_city
31
research centres
public
1
country
person_search
33
investigators

Specializations

Myelodysplastic Syndromes and del(5q) Disease

Associazione Qol-One funds clinical research in myelodysplastic syndromes, with a specific focus on del(5q) disease and lower-risk forms defined by IPSS-R categories. The sponsored trials address patients with limited prior treatment options and ongoing bone marrow failure.

  • Lower-risk MDS
  • del(5q) subtype
  • Bone marrow blast count

The research landscape includes patients with very low, low, and intermediate risk disease, reflecting a therapeutic interest in clinically significant but less advanced myelodysplastic conditions.

Anemia and Red Blood Cell Transfusion Dependence

The sponsor supports studies centered on anemia associated with myelodysplastic syndromes, especially in individuals who require ongoing red blood cell transfusions. This area includes patients with persistent symptomatic burden and limited hematologic recovery.

  • Transfusion-dependent anemia
  • RBC transfusion independence
  • Hematologic response

Clinical interest extends to improving erythroid support and reducing the need for repeated transfusion care in this population.

Thrombocytopenia in Myelodysplastic Syndromes

Associazione Qol-One also funds research into thrombocytopenia linked to lower- and intermediate-risk myelodysplastic syndromes. This reflects attention to platelet-related complications that contribute to bleeding risk and broader hematologic instability.

  • Platelet response
  • Long-term safety
  • Hematologic support

The therapeutic scope includes treatment strategies aimed at restoring or sustaining platelet counts in patients with chronic marrow dysfunction.

Refractory and Treatment-Intolerant Patient Populations

The sponsor’s clinical research interest includes patients who are refractory, resistant, or intolerant to prior therapies, particularly ESA and lenalidomide. These studies focus on individuals with unmet needs after standard treatment exposure.

  • Prior treatment failure
  • Therapy intolerance
  • Supportive hematology care

This area emphasizes clinical research in patients requiring alternative approaches for marrow failure–related cytopenias.

Sponsored Trials

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 2 total (0% not shared with other sponsors)

This sponsor works with 2 molecules, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
23%
Return partnership rate
7 of 31 sites collaborated multiple times

This sponsor has worked with 31 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Hemic and Lymphatic Diseases2 trials
    249 other sponsors

Partnered Research Centres

31 centres
location_city
assignment6
A.O.SS Antonio Biagio e Cesare Arrigo Alessandria
Address
Via Venezia, 16 - 15121, 16121 Alessandria
Learn morearrow_forward
location_city
assignment5
AOU Ospedali Riuniti Umberto I°-Lancisi-Salesi di Ancona
Address
via Conca 71, 60126 Torrette (AN), Ancona
Learn morearrow_forward
location_city
assignment6
ASL PESCARA-Presidio Ospedaliero Pescara
Address
Via Fonte Romana 8, 65124 Pescara
Learn morearrow_forward
location_city
assignment413
ASST Grande Ospedale Metropolitano Niguarda
Address
Piazza Dell'ospedale Maggiore 3, 20162 Milan
Learn morearrow_forward
location_city
assignment4
Azienda Ospedaliera di Cosenza - P.O. ANNUNZIATA
Address
Viale della Repubblica snc, Cosenza
Learn morearrow_forward
location_city
assignment94
Azienda Ospedaliera S Maria Di Terni
Address
Viale Tristano Di Joannuccio 1, 05100 Terni
Learn morearrow_forward
Page 1 of 6

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Associazione Qol-One.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.